Latest news with #ILMN
Yahoo
30-05-2025
- Business
- Yahoo
Illumina Introduces a New AI algorithm PromoterAI: Stock to Gain?
Illumina Inc. ILMN recently introduced PromoterAI, a new AI algorithm that accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome. PromoterAI turns data into insights to help researchers accelerate new breakthroughs in diagnosis for rare diseases. It is the latest addition to the company's artificial intelligence ("AI") and software portfolio. Since the announcement on May 29, ILMN's shares declined 0.2%, closing at $84.28 yesterday. The company is breaking new ground with AI technology. In 2019, the Illumina Artificial Intelligence Lab released SpliceAI, a deep learning tool for interpreting noncoding cryptic splice mutations. In 2023, Illumina released PrimateAI-3D, which predicts the pathogenicity of protein-coding variants based on evolutionary conservation and protein structure. PromoterAI is the latest genomic AI algorithmic innovation from Illumina. As a result, we expect the news to boost market sentiment toward ILMN stock. Illumina presently has a market capitalization of $13.34 billion. The company's earnings yield of 5.1% sits comfortably against the industry's -31.7%. It delivered a trailing four-quarter average earnings surprise of 56.4%. Built on state-of-the-art deep learning neural networks, PromoterAI brings unprecedented precision to the interpretation of promoter variants. With PromoterAI applied to whole-genome sequencing ("WGS") data analysis, clinical researchers are empowered to better understand the etiology and drug target potential for rare genetic diseases, common diseases and oncology. PromoterAI will be accessible through Illumina Connected Software, and it is now available as part of DRAGEN secondary analysis. Precomputed PromoterAI scores for all human promoter single-nucleotide variants are freely available for academic and noncommercial research use. Currently, only about 30% of rare disease patients receive an accurate diagnosis from exome sequencing. For many patients, insights may be hidden in what are known as "noncoding regions," which comprise over 98% of the genome and may hold the key to increasing the diagnostic rate. Promoters are key noncoding elements that define where transcription of a gene begins. When promoters are disrupted by genetic mutations, it can have profound consequences for downstream gene expression. The PromoterAI algorithm interprets the genetic sequence of promoters, thus opening the door to precise diagnoses for more patients with rare diseases. Image Source: Zacks Investment Research Per Dimension Market Research's report, AI in the genomics market is estimated to be valued at $1.40 billion in 2025. It is further anticipated to reach $44.93 billion by 2034 at a compound annual growth rate of 47%. Key factors driving the market growth are increasing demand for precision medicine, rising R&D expenditure and growing demand for effective handling tools for managing large data. On Tuesday, Illumina received approval from Japan's Ministry of Health, Labour and Welfare for TruSightTM Oncology (TSO) Comprehensive for Class III/IV Medical Device (Specially Controlled Medical Device). The TSO Comprehensive is the first U.S. FDA-approved, distributable comprehensive genomic profiling in vitro diagnostics (IVD) kit with pan-cancer CDx claims in the United States. Over the past three months, ILMN's shares have risen 0.1% against the industry's 8.5% decline. Illumina currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space include Phibro Animal Health PAHC, Hims & Hers Health HIMS and Prestige Consumer Healthcare PBH. While Phibro Animal Health sports a Zacks Rank #1 (Strong Buy) at present, Hims & Hers Health and Prestige Consumer Health carry a Zacks Rank #2 (Buy) each. You can see the complete list of today's Zacks #1 Rank stocks here. Estimates for Phibro Animal Health's fiscal 2025 earnings per share have jumped 3.6% to $2.01 in the past 30 days. Shares of the company have rallied 37.9% in the past year compared with the industry's 10.1% growth. Its earnings yield of 8.7% compares comfortably with the industry's 0.5%. PAHC's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 30.6%. Hims & Hers Health's shares have surged 172.5% in the past year. Estimates for the company's 2025 earnings per share have jumped 12.5% to 72 cents in the past 30 days. HIMS' earnings beat estimates in two of the trailing four quarters, matched in one and missed in the other, the average surprise being 19.6%. In the last reported quarter, it posted an earnings surprise of 66.7%. Estimates for Prestige Consumer Healthcare's fiscal 2026 earnings per share have increased 1 cent to $4.77 in the past 30 days. Shares of the company have jumped 37.2% in the past year compared with the industry's 10.1% growth. PBH's earnings surpassed estimates in three of the trailing four quarters and matched on one occasion, the average surprise being 2.8%. In the last reported quarter, it delivered an earnings surprise of 1.5%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Illumina, Inc. (ILMN) : Free Stock Analysis Report Prestige Consumer Healthcare Inc. (PBH) : Free Stock Analysis Report Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
30-05-2025
- Health
- Yahoo
Illumina, Inc. (ILMN) Unveils AI Breakthrough for Rare Disease Diagnosis
Illumina, Inc. (NASDAQ:ILMN) has introduced PromoterAI, a breakthrough AI tool designed to detect disease-causing mutations in the noncoding promoter regions of the genome, areas often overlooked in clinical diagnostics. Featured in Science, the study shows PromoterAI could explain up to 6% of undiagnosed rare disease cases, potentially doubling diagnostic success when paired with existing AI tools. A research facility with medical professionals surrounded by diagnostic equipment. While most current diagnostics focus on protein-coding regions, PromoterAI analyzes promoter sequences, key regulators of gene activity, using deep learning. 'This opens new possibilities for patients who previously had no genetic answers,' said Dr. Kyle Farh, head of Illumina, Inc. (NASDAQ:ILMN)'s AI Lab. The tool joins Illumina, Inc. (NASDAQ:ILMN)'s AI portfolio, including SpliceAI and PrimateAI-3D, and integrates with its DRAGEN analysis system. It is freely available for academic research through Illumina Connected Software, offering precomputed scores to prioritize harmful mutations quickly. While we acknowledge the potential of ILMN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ILMN and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None.
Yahoo
30-05-2025
- Health
- Yahoo
Illumina, Inc. (ILMN) Unveils AI Breakthrough for Rare Disease Diagnosis
Illumina, Inc. (NASDAQ:ILMN) has introduced PromoterAI, a breakthrough AI tool designed to detect disease-causing mutations in the noncoding promoter regions of the genome, areas often overlooked in clinical diagnostics. Featured in Science, the study shows PromoterAI could explain up to 6% of undiagnosed rare disease cases, potentially doubling diagnostic success when paired with existing AI tools. A research facility with medical professionals surrounded by diagnostic equipment. While most current diagnostics focus on protein-coding regions, PromoterAI analyzes promoter sequences, key regulators of gene activity, using deep learning. 'This opens new possibilities for patients who previously had no genetic answers,' said Dr. Kyle Farh, head of Illumina, Inc. (NASDAQ:ILMN)'s AI Lab. The tool joins Illumina, Inc. (NASDAQ:ILMN)'s AI portfolio, including SpliceAI and PrimateAI-3D, and integrates with its DRAGEN analysis system. It is freely available for academic research through Illumina Connected Software, offering precomputed scores to prioritize harmful mutations quickly. While we acknowledge the potential of ILMN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ILMN and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28-05-2025
- Business
- Yahoo
Illumina's TSO Comprehensive Earns Japan's Approval: Stock to Gain?
Illumina, Inc. ILMN has received approval from Japan's Ministry of Health, Labour and Welfare for TruSightTM Oncology (TSO) Comprehensive for Class III/IV Medical Device (Specially Controlled Medical Device). As genomic insights continue to drive breakthroughs in cancer treatment, the test is designed to make precision oncology more accessible to oncologists and patients. The latest development bolsters the company's oncology portfolio. Illumina also stated that its clinical oncology offerings will be featured at the ASCO Annual Meeting in Chicago, to be held between May 30 and June 3. Since the announcement on May 26, ILMN shares jumped 2.6%, closing at $82.49 yesterday. The company's oncology portfolio offers versatile, scalable solutions — from low to high-throughput instruments — to meet global customer needs. Through pharmaceutical partnerships, it is developing an expanding pipeline of companion diagnostics (CDx), ultimately driving progress in cancer diagnostics and precision medicine. As a result, we expect the news to boost market sentiment toward ILMN stock. Illumina presently has a market capitalization of $12.72 billion. The company's earnings yield of 5.3% sits comfortably against the industry's -31.5% yield. It delivered an earnings beat of 56.4%, on average, in the trailing four quarters. The TSO Comprehensive is the first U.S. FDA-approved, distributable comprehensive genomic profiling in vitro diagnostics (IVD) kit with pan-cancer CDx claims in the United States. A separate CE-marked version was launched in Europe in 2022. Image Source: Zacks Investment Research The single test includes analysis of DNA and RNA variants and interrogates more than 500 genes to profile a patient's solid tumor, helping increase the likelihood of identifying clinically actionable biomarkers that enable targeted therapy selection or clinical trial enrolment. Powered by a streamlined, automated sample-to-report workflow, the CGP test will enable clinicians in Japan to accelerate access to personalized medicine decisions with greater efficiency and precision. Per a Research report, the global precision genomic testing market was valued at $15.49 billion in 2024 and is expected to grow at a compound annual rate of 14.8% through 2030. This market includes a variety of diagnostic tools and techniques to analyze genetic information, leading to more accurate diagnoses, targeted therapies and improved patient outcomes. Rising demand for precision genomic testing is fueled by the need for early disease detection, effective treatment planning and better management of chronic conditions. This month, the company launched the DRAGEN version 4.4 software (v4.4), which includes out-of-the-box oncology applications for clinical research and support for newly announced Illumina multiomics assays. DRAGEN v4.4 enhancements will simplify next-generation sequencing (NGS) analysis for customers while expanding their capabilities. In addition, Illumina, in partnership with Inc., announced the development of the largest commercially available clinical multiomic dataset from 25,000 patients treated with glucagon-like peptide-1 (GLP-1) receptor agonist therapies. The dataset will be made available to the pharma community to advance drug discovery and development. Over the past three months, ILMN shares have fallen 7.1% compared with the industry's 11.6% decline. Illumina currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space include Phibro Animal Health PAHC, Hims & Hers Health HIMS and Prestige Consumer Healthcare PBH. While Phibro Animal Health sports a Zacks Rank #1 (Strong Buy) at present, Hims & Hers Health and Prestige Consumer Health each carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here. Estimates for Phibro Animal Health's fiscal 2025 earnings per share have jumped 3.6% to $2.01 in the past 30 days. Shares of the company have rallied 37.9% in the past year compared with the industry's 10.1% growth. Its earnings yield of 8.7% compares comfortably with the industry's 0.5% yield. PAHC's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 30.6%. Hims & Hers Health shares have surged 172.5% in the past year. Estimates for the company's 2025 earnings per share have jumped 12.5% to 72 cents in the past 30 days. HIMS' earnings beat estimates twice in the trailing four quarters, matched in one and missed on another occasion, the average surprise being 19.6%. In the last reported quarter, it posted an earnings surprise of 66.7%. Estimates for Prestige Consumer Healthcare'sfiscal 2026 earnings per share have increased 1 cent to $4.77 in the past 30 days. Shares of the company have jumped 37.2% in the past year compared with the industry's 10.1% growth. PBH's earnings surpassed estimates in three of the trailing four quarters and matched on one occasion, the average surprise being 2.8%. In the last reported quarter, it delivered an earnings surprise of 1.5%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Illumina, Inc. (ILMN) : Free Stock Analysis Report Prestige Consumer Healthcare Inc. (PBH) : Free Stock Analysis Report Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21-05-2025
- Business
- Yahoo
Illumina Stock to Gain From the Launch of New DRAGEN v4.4 Software
Illumina, Inc. ILMN recently unveiled the DRAGEN version 4.4 software (v4.4), the industry's most comprehensive secondary analysis solution. The latest version includes out-of-the-box oncology applications for clinical research, greater accuracy and support for the company's newly announced multiomics assays. The DRAGEN v4.4 enhancements are expected to simplify NGS analysis for customers while expanding their capabilities. The University Hospital of Tübingen in Germany is among the first adopters of the latest DRAGEN version for their groundbreaking study to evaluate the clinical utility of advanced secondary analysis on whole-genome germline testing. Since the announcement on May 13, ILMN shares jumped 3.3% to close at $82.95 yesterday. Providing labs with ready-to-use analysis applications simplifies oncology biomarker detection and reduces customer complexities. By integrating with Illumina Connected Insights, the applications enable a streamlined workflow for analysis and interpretation across diverse research areas, including genetic diseases, oncology, multiomics, infectious diseases and population genomics. Accordingly, we expect the latest development to boost market sentiment toward ILMN stock. Illumina presently has a market capitalization of $13.13 billion. The company's earnings yield of 5.2% sits comfortably against the industry's -33.3% yield. It delivered an earnings beat of 56.4%, on average, in the trailing four quarters. DRAGEN v4.4 will offer "push-button" analysis for oncology workflows, including the first and only commercially available heme WGS application, Solid WGS DNA Tumor-Normal, and pipelines for molecular residual disease (MRD) and WGS analysis, with more coming soon. It will also support the new and emerging multiomics assays, including Illumina Single Cell 3'RNA Prep and Illumina Protein Prep, and in the future will support the anticipated 5-base solution for methylation analysis and Illumina's spatial technology solution. Image Source: Zacks Investment Research DRAGEN v4.4 marks a 30% increase in SV calling accuracy — the software's biggest leap to date — driven by advancements in the multigenome mapper with pangenome reference. These advances help close the gap in structural variant calling accuracy between short- and long-read sequencing capabilities. DRAGEN v4.4 introduces a personalized pangenome reference capability that delivers a 20% boost in accuracy of single-nucleotide variant and indel calling. Furthermore, DRAGEN v4.4 supports new AWS F2 instance types, enabling faster turnaround times and improved scalability in the cloud. Per a Grand View Research report, the global NGS data analysis market was valued at $999.4 million in 2024 and is expected to grow at a compound annual rate of 23.1% by 2030. The rising use of sequencing platforms in clinical diagnosis, due to reduced installation costs, is expected to fuel the market's growth. This month, Illumina, in collaboration with Inc., announced the development of the largest commercially available clinical multiomic dataset from 25,000 patients treated with glucagon-like peptide-1 (GLP-1) receptor agonist therapies. The dataset will be made available to the pharma community to advance drug discovery and development. Over the past three months, ILMN shares have fallen 12% against the industry's 12.8% growth. Illumina currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space include Hims & Hers Health HIMS, Phibro Animal Health PAHC and Prestige Consumer Healthcare PBH. Each of these carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Estimates for Hims & Hers Health's 2025 earnings per share have jumped 21.2% to 63 cents in the past 30 days. Shares of the company have surged 255% in the past year compared with the industry's 21.2% growth. Its earnings yield of 1.1% compares comfortably with the industry's -9.7% yield. HIMS' earnings surpassed estimates in two of the trailing four quarters, matched in one and missed on another occasion, the average surprise being 19.6%. Phibro Animal Health shares have rallied 31.3% in the past year. Estimates for the company's fiscal 2025 earnings per share have jumped 3.6% to $2.01 in the past 30 days. PAHC's earnings beat estimates in each of the trailing four quarters, the average surprise being 30.6%. In the last reported quarter, it posted an earnings surprise of 21.2%. Estimates for Prestige Consumer Healthcare'sfiscal 2026 earnings per share have increased 1 cent to $4.77 in the past 30 days. Shares of the company have jumped 36.8% in the past year compared to the industry's 10.8% growth. PBH's earnings surpassed estimates in three of the trailing four quarters and matched on one occasion, the average surprise being 2.8%. In the last reported quarter, it delivered an earnings surprise of 1.5%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Illumina, Inc. (ILMN) : Free Stock Analysis Report Prestige Consumer Healthcare Inc. (PBH) : Free Stock Analysis Report Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
